You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
永和智控(002795.SZ)子公司擬8860萬元收購達州中科腫瘤醫院95%股權
格隆匯 01-13 19:57

格隆匯1月13日丨永和智控(002795.SZ)公佈,公司全資子公司成都永和成於2020年1月10日與成都禹鍩普得簽署了《關於達州中科腫瘤醫院有限公司之股權收購協議》,成都永和成擬以現金支付方式購買成都禹鍩普得持有的達州中科95%股權,股權轉讓價格為8860萬元。此次股權收購事項完成後,達州中科將成為成都永和成控股子公司,納入合併範圍。

達州中科腫瘤醫院是以腫瘤放療為主的專科醫院,致力於各種腫瘤的診斷及綜合治療。醫院建築面積1萬平方米,設置牀位100多張。

醫院設有內科、外科、腫瘤科、放療科、醫學檢驗科、藥劑科、影像科(CT診斷、磁共振成像診斷、超聲診斷、心電診斷)等十多個科室,能滿足各類腫瘤病人的治療需求。

達州中科腫瘤醫院目前配置有先進的大型診療設備如:頭部伽瑪刀、體部伽瑪刀、電子直線加速器、核磁共振、CT、全自動凝血分析儀、生化分析儀、全自動血細胞分析儀、全自動化學發光測定儀、尿液分析儀、電解質分析儀、數字X光機(DR)、彩超、心電圖等世界前列醫用設備。

截至目前,成都禹鍩普得持有標的公司100%股權。此次收購完成後,成都永和成將持有標的公司95%股權。

達州中科的收購標誌着公司首次向醫療健康產業逐步轉型取得成功,是公司在國內醫療服務市場領域的第一個落地項目,對公司未來的產業佈局和戰略規劃均具有重要意義,符合公司的長期發展戰略。

此次交易對價以現金方式支付,不涉及發行股份,不會對公司的股權結構產生影響。此次交易完成後,成都永和成將持有達州中科95%的股權,標的公司將納入公司合併財務報表範圍。此次股權收購將有利於改善上市公司經營情況,提高上市公司資產質量,增強上市公司持續盈利能力。不會損害中小股東的利益,不會對公司的財務狀況及經營成果造成重大不利影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account